ACR Convergence 2022

November 10-14, 2022. Philadelphia, PA.

View by Number View by Title View Sessions

View by Date

Monday, November 14, 2022

1:00PM-3:00PM: Abstract Number: 1806

Characteristics and Comorbidity Burden of Phase 3 Clinical Trial Participants Who Did and Did Not Experience Acute Gout Flares During Biweekly Pegloticase Dosing

Metabolic and Crystal Arthropathies – Basic and Clinical Science Poster

1:00PM-3:00PM: Abstract Number: 2017

Characteristics and Prognosis Factors of Relapse or Death for Non-Hodgkin Lymphomas in Primary Sjögren Syndrome

Sjögren's Syndrome – Basic and Clinical Science Poster

1:00PM-3:00PM: Abstract Number: 1830

Characteristics of Arthritis in Familial Mediterranean Fever Patients

Miscellaneous Rheumatic and Inflammatory Diseases Poster III

1:00PM-3:00PM: Abstract Number: 1849

Characteristics of Patients with Primary Retinal Vasculitis at a Tertiary Referral Center

Miscellaneous Rheumatic and Inflammatory Diseases Poster III

1:00PM-3:00PM: Abstract Number: 1794

Characteristics of Patients with Repeat Visits for Acute Gout at a University Hospital Emergency Department

Metabolic and Crystal Arthropathies – Basic and Clinical Science Poster

1:00PM-3:00PM: Abstract Number: 1738

Characterization of T Cell Subsets in the Synovium of Chronic Inflammatory Joint Diseases

T Cell Biology and Targets in Autoimmune and Inflammatory Disease Poster

1:00PM-3:00PM: Abstract Number: 1848

Characterizing Nailfold Capillary Changes in Dermatomyositis with a Dermatoscope

Miscellaneous Rheumatic and Inflammatory Diseases Poster III

1:00PM-3:00PM: Abstract Number: 1925

Characterizing Phenotypic Changes by SARS-CoV-2 Variant in Multisystem Inflammatory Syndrome in Children (MIS-C): A Single Institution Case Series

Pediatric Rheumatology – Clinical Poster III: Other

1:00PM-3:00PM: Abstract Number: 2037

Childhood-onset Sjögren’s Syndrome Is Characterised by Dysregulated of B and T Memory Cell Frequencies: A Pilot Immunophenotyping Analysis of This Rare Disease Phenotype

Sjögren's Syndrome – Basic and Clinical Science Poster

1:00PM-3:00PM: Abstract Number: 1740

Chronic Inflammation in Patients with Rheumatoid Arthritis or Spondyloarthritis Alters Regulatory T Cells Identity

T Cell Biology and Targets in Autoimmune and Inflammatory Disease Poster

1:00PM-3:00PM: Abstract Number: 1706

Clinical and Immunological Factors Associated with Chronic Post-COVID19 Syndrome 12 Months After Acute Infection

Innate Immunity Poster: Basic and Translational Science

1:00PM-3:00PM: Abstract Number: 2156

Clinical Benefits of Lung Transplantation in Systemic Sclerosis-related Interstitial Lung Disease; A Single-Center Retrospective Study

Systemic Sclerosis and Related Disorders – Clinical Poster III

1:00PM-3:00PM: Abstract Number: 1948

Clinical Characteristics and Outcomes of Pediatric ANCA-Associated Vasculitis Patients: Single-Center Inception Cohort

Pediatric Rheumatology – Clinical Poster III: Other

1:00PM-3:00PM: Abstract Number: 1852

Clinical Efficacy and Safety of Guselkumab Maintenance Therapy in Patients with Moderately to Severely Active Crohn’s Disease: Week 48 Analyses from the Phase 2 GALAXI 1 Study

Miscellaneous Rheumatic and Inflammatory Diseases Poster III

1:00PM-3:00PM: Abstract Number: 1835

Clinical Features of Patients with Sarcoidosis and Concomitant Connective Tissue Disease

Miscellaneous Rheumatic and Inflammatory Diseases Poster III

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

ACR Abstract Embargo Policy

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. Academic institutions, private organizations and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part a scientific presentation or presentation of additional new information that will be available at the time of the meeting) is under embargo until Saturday, November 11, 2023.

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying financial and other sponsors about this policy. If you have questions about the abstract embargo policy, please contact the public relations department at [email protected].

Copyright Policy

View ACR Policies.